News

Latest News

• July 24, 2023
  

  Aptitude partners with Bill & Melinda Gates Foundation (BMGF) to accelerate the commercialization of the Metrix Multiplex STI panel for Point-of-Care and Over-the-Counter use. This product will transform access to critical diagnostic information in the domestic market and in Low and Middle Income Countries.
  

  Read More
  

• April 20, 2023
  

  Aptitude Receives up to $54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use.
  

  Read More
  

• October 18, 2022
  

  Aptitude received FDA Emergency Use Authorization for the Metrix™ COVID-19 Test, the world's first saliva/swab based molecular test for at-home and over-the-counter use without physician supervision.
  

  Read More
  

• August 3, 2022
  

  Aptitude submitted request to the FDA for Emergency Use Authorization seeking first saliva/swab based molecular over-the-counter COVID-19 test.
  

• January 27, 2021
  

  Aptitude has received multi-million dollar funding to develop its next-generation molecular diagnostics platform through regulatory approval.
  

• December 21, 2020
  

  Aptitude received California Clinical Laboratory Improvement Amendments (CLIA) license for high-complexity molecular testing.
  

• July 10, 2020
  

  Aptitude was admitted into the prestigious NIH RADx program to develop COVID-19 tests that are easier to use, easier to access, and more accurate.